These findings are supported by previous studies, which reported that SLC44A4 overexpression is associated with the onset of PRAD and PAAD (Mattie et al., 2016; Ma et al., 2019; McHugh et al., 2019). Here, SLC44A4 is linked to pancreatic adenocarcinoma.